DVAX - ダイナバックス・テクノロジ―ズ (Dynavax Technologies Corporation) ダイナバックス・テクノロジ―ズ

 DVAXのチャート


 DVAXの企業情報

symbol DVAx
会社名 Dynavax Technologies Corp (ダイナバックス・テクノロジ―ズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ダイナバクス・テクノロジーズ(Dynavax Technologies Corporation)は臨床段階の免疫療法会社である。同社はトール様受容体(TLR)刺激を通じて身体の本能と適応免疫応答を活用することに集中する。同社の製品候補は複数の癌適応症、B型肝炎の予防ワクチン、および喘息疾患修正療法として開発される。同社の製品はHEPLISAV-B、AZD1419、SD-101、DV281、DV230FとDV1001を含む。HEPLISAV-Bは治験成人のB型肝炎ワクチンである。AZD1419は喘息の治療として開発される。SD-101は癌に対する免疫応答を誘発するように設計される治験用TLR9アゴニストである。DV281は原発性肺腫瘍および肺転移への集中送達のためのTLR9アゴニストである。DV230Fは肝腫瘍の治療に適応する。DV1001は複数悪性腫瘍のTLR7、8アゴニストを標的とする。DV230FとDV1001は開発の前臨床段階である。   ダイナバックス・テクノロジ―ズは米国の臨床検査段階のバイオ医薬品会社。感染症、炎症性疾、自己免疫疾患治療薬の研究、開発に従事。候補製剤にはB型肝炎ワクチン「ヘプリサブ」、自己免疫疾患治療用「DV1179」、喘息治療用「AZD1419」、癌免疫療法「SD-101」などがある。   Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza.
本社所在地 2929 Seventh Street Suite 100 Berkeley CA 94710-2753 USA
代表者氏名 Arnold L. Oronsky アーノルドエルオロスキー
代表者役職名 Independent Chairman of the Board
電話番号 +1 510-848-5100
設立年月日 35278
市場名 NASDAQ Small Cap
ipoyear 2004年
従業員数 170人
url www.dynavax.com
nasdaq_url https://www.nasdaq.com/symbol/dvax
adr_tso
EBITDA EBITDA(百万ドル) -115.44000
終値(lastsale) 11.07
時価総額(marketcap) 693154537.02
時価総額 時価総額(百万ドル) 700.66840
売上高 売上高(百万ドル) 1.49300
企業価値(EV) 企業価値(EV)(百万ドル) 584.39640
当期純利益 当期純利益(百万ドル) -127.95100
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Dynavax Technologies Corporation revenues increased from $253K to $1.4M. Net loss increased 72% to $78.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative - Balancing v increase from $2.3M to $17.5M (expense).

 DVAXのテクニカル分析


 DVAXのニュース

   Dynavax Technologies (DVAX) Q1 2022 Earnings Call Transcript  2022/05/06 13:01:05 The Motley Fool
DVAX earnings call for the period ending March 31, 2022.
   Dynavax Technologies Corporation 2022 Q1 - Results - Earnings Call Presentation  2022/05/06 10:54:50 Seeking Alpha
The following slide deck was published by Dynavax Technologies Corporation in conjunction with their 2022 Q1 earnings call.
   Dynavax Technologies Corp (DVAX) CEO Ryan Spencer on Q1 2022 Results - Earnings Call Transcript  2022/05/06 00:17:02 Seeking Alpha
Dynavax Technologies Corp (NASDAQ:NASDAQ:DVAX) Q1 2022 Earnings Conference Call May 05, 2022, 16:30 ET Company Participants Nicole Arndt - Senior Manager, IR Ryan Spencer - CEO &…
   Dynavax GAAP EPS of $0.26 beats by $0.02, revenue of $114M misses by $40.29M  2022/05/05 20:06:13 Seeking Alpha
Dynavax press release (DVAX): Q1 GAAP EPS of $0.26 beats by $0.02.Revenue of $114M (+36.8% Y/Y) misses by $40.29M.CpG 1018 adjuvant net product revenue of $91.5M, up 23% from $74.6M…
   Dynavax Technologies Corporation (NASDAQ: DVAX) : Investors Should Not Dump DVAX Stock In 2022  2022/05/04 12:30:00 Marketing Sentinel
In the last trading session, 1.41 million Dynavax Technologies Corporation (NASDAQ:DVAX) shares changed hands as the company’s beta touched 1.42. With the company’s per share price at $9.15 changed hands at -$0.15 or -1.61% during last session, the market valuation stood at $1.21B. DVAX’s last price was a discount, traded about -133.77% off its 52-week … Dynavax Technologies Corporation (NASDAQ: DVAX) : Investors Should Not Dump DVAX Stock In 2022 Read More »
   Amgen''s (AMGN) KRAS Inhibitor Gets Nod in Japan for Lung Cancer | Investing.com  2022/01/21 19:40:08 Investing.com
Stocks Analysis by Zacks Investment Research covering: Amgen Inc, Dynavax Technologies Corporation, Mirati Ther, AnaptysBio Inc. Read Zacks Investment Research''s latest article on Investing.com
   Dynavax reinstated Buy at Goldman Sachs on potential of adjuvant, HBV prospects  2022/01/06 14:04:15 Seeking Alpha
Dynavax Technologies (DVAX) is trading ~4.8% higher in the pre-market after Goldman Sachs reinstated its coverage on Wednesday with a Buy recommendation citing the potential of
   Dynavax to Present at the H.C. Wainwright Virtual BioConnect 2022 Conference  2022/01/05 21:05:00 Business Insider Markets
EMERYVILLE, Calif., Jan. 5, 2022 /PRNewswire/ -- Dynavax Technologies Corporation
   Dynavax Technologies (NASDAQ:DVAX) Stock Price Down 3.9%  2021/12/24 11:04:43 Transcript Daily
Shares of Dynavax Technologies Co. (NASDAQ:DVAX) were down 3.9% during mid-day trading on Wednesday . The company traded as low as $13.66 and last traded at $13.68. Approximately 5,540 shares traded hands during trading, a decline of 100% from the average daily volume of 3,946,220 shares. The stock had previously closed at $14.23. Several research […]
   Analysts Anticipate Dynavax Technologies Co. (NASDAQ:DVAX) Will Post Earnings of $0.65 Per Share  2021/12/23 13:18:43 Transcript Daily
Equities analysts expect Dynavax Technologies Co. (NASDAQ:DVAX) to announce earnings of $0.65 per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Dynavax Technologies earnings. The highest EPS estimate is $0.73 and the lowest is $0.57. Dynavax Technologies reported earnings of ($0.14) per share in the same quarter []
   Robinhood Markets, Mednax, California Resources, and Other Stocks See Action From Activist Investors  2021/09/03 20:05:00 Barron''s
Activists report to the SEC on Robinhood Markets, Oscar Health, CryoPort, Dynavax Technologies, California Resources, and Mednax
   The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical  2021/08/31 12:05:06 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN ) Alkermes plc (NASDAQ: ALKS ) Axonics, Inc. (NASDAQ: AXNX ) Bio-Techne Corporation (NASDAQ: TECH ) BioLife Solutions, Inc. (NASDAQ: BLFS ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE ) Clearside Biomedical, Inc. (NASDAQ: CLSD ) Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX ) Cytokinetics, Incorporated (NASDAQ: CYTK ) Dermata Therapeutics, Inc. (NASDAQ: DRMA ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Eliem Therapeutics, Inc. (NASDAQ: ELYM ) (IPOed Aug. 10) Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA ) IVERIC bio, Inc. (NASDAQ: ISEE ) Kezar Life Sciences, Inc. (NASDAQ: KZR ) Merit Medical Systems, Inc. (NASDAQ: MMSI ) MiMedx Group, Inc. (NASDAQ: MDXG ) PDS Biotechnology Corporation (NASDAQ: PDSB ) Pieris Pharmaceuticals, Inc.
   The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration  2021/08/27 11:35:25 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN ) Alkermes plc (NASDAQ: ALKS ) BeyondSpring Inc. (NASDAQ: BYSI ) ( moved on a co-development and commercialization agreement for chemotherapy-induced neutropenia treatment candidate) BioLife Solutions, Inc. (NASDAQ: BLFS ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN ) DexCom, Inc. (NASDAQ: DXCM ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Erasca, Inc. (NASDAQ: ERAS ) Fulcrum Therapeutics, Inc. (NASDAQ: FULC ) Imago BioSciences, Inc. (NASDAQ: IMGO ) MiMedx Group, Inc. (NASDAQ: MDXG ) Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE ) Nuvalent, Inc. (NASDAQ: NUVL ) (IPOed July 29) PDS Biotechnology Corporation (NASDAQ: PDSB ) Prothena Corporation plc (NASDAQ: PRTA ) Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) Repligen Corporation (NASDAQ: RGEN ) ShockWave Medical, Inc. (NASDAQ: SWAV ) Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 26) Alzamend Neuro, Inc. (NASDAQ: ALZN ) Edgewise Therapeutics, Inc. (NASDAQ: EWTX ) FibroGen, Inc. (NASDAQ: FGEN ) MaxCyte, Inc. (NASDAQ: MXCT ) Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM ) Theravance Biopharma, Inc. (NASDAQ: TBPH ) TScan Therapeutics, Inc. (NASDAQ: TCRX ) Stocks In Focus Immutep Announces Award of Chinese Patent For Out-licensed Antibody Treatment Candidate For Cancer and Infectious Disease Immutep Limited (NASDAQ: IMMP ) announced the grant of a patent entitled "Antibody molecules to LAG-3 and uses thereof"
   The Daily Biotech Pulse: Early Approval For Ascendis'' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO  2021/08/26 12:09:13 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 25) Abbvie Inc. (NYSE: ABBV ) BioLife Solutions, Inc. (NASDAQ: BLFS ) (reacted to the news of inclusion in the S&P SmallCap 600 Index) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Catalent Inc (NYSE: CTLT ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Fulcrum Therapeutics, Inc. (NASDAQ: FULC ) Medtronic plc (NYSE: MDT ) MiMedx Group, Inc. (NASDAQ: MDXG ) Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE ) Nuvalent, Inc. (NASDAQ: NUVL ) (IPOed July 29) PDS Biotechnology Corporation (NASDAQ: PDSB ) Regencell Bioscience Holdings Limited (NASDAQ: RGC ) Repligen Corporation (NASDAQ: RGEN ) ShockWave Medical, Inc. (NASDAQ: SWAV ) Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 25) Aerovate Therapeutics, Inc. (NASDAQ: AVTE ) Alzamend Neuro, Inc. (NASDAQ: ALZN ) Theravance Biopharma, Inc. (NASDAQ: TBPH ) TScan Therapeutics, Inc. (NASDAQ: TCRX ) Stocks In Focus Ascendis Gets FDA Nod For Pediatric Growth Hormone Deficiency Treatment Ascendis Pharma A/S (NASDAQ: ASND ) said the Food and Drug Administration has approved Skytrofa (lonapegsomatropin-tcgd) for the treatment of pediatric patients one year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone.
   Redmile Group, LLC Buys Verve Therapeutics Inc, The Beauty Health Co, Nurix Therapeutics Inc, ...  2021/08/24 17:38:03 GuruFocus
Related Stocks: ONEM , SLQT , VERV , SKIN , NRIX , ZY , ALXO , LFST , MDT , GNMK , BIIB , VSPR , QURE , DVAX ,

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ダイナバックス・テクノロジ―ズ DVAX Dynavax Technologies Corporation)

 twitter  (公式ツイッターやCEOツイッターなど)